Buprenorphine safe for use in Hospitalized patients with Acute Hepatitis A: Study
Buprenorphine has a good safety profile when administered to hospitalized patients with Acute Hepatitis A suggests a study published in the Journal of Addiction Medicine.
Hepatitis A is an inflammation of the liver that can cause mild to severe illness. The hepatitis A virus (HAV) is transmitted by ingesting contaminated food and water or direct contact with an infectious person. Patients are admitted if they are showing any signs or symptoms suggestive of severe complications. Buprenorphine is FDA-approved for acute pain, chronic pain, and opioid dependence. It is not known whether buprenorphine/naloxone (bup/nx) can be safely initiated in hospitalized patients with acute hepatitis A infection.
A group of researchers from U.S.A assessed liver function and tolerability of buprenorphine/naloxone (bup/nx) induction in patients with acute Hepatitis A Virus (HAV).
The researchers conducted retrospective review of patients (N = 31) admitted to a tertiary care facility for acute Hepatitis A Virus (HAV) who were evaluated by an addiction medicine consultant.
The results of the study are as follows:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.